These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. Smith WT; Londborg PD; Blomgren SL; Tollefson GD; Sayler ME J Clin Psychopharmacol; 1999 Apr; 19(2):125-31. PubMed ID: 10211913 [TBL] [Abstract][Full Text] [Related]
8. LAS 30451: a novel 5-HT3 antagonist. Martin M; Rosell R; Guillem V; Díaz-Rubio E; Moreno I; Soriano V; Fernández A; Pérez A Eur J Cancer; 1993; 29A Suppl 1():S33-4. PubMed ID: 8427723 [No Abstract] [Full Text] [Related]
9. Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs. Gidda JS; Evans DC; Cohen ML; Wong DT; Robertson DW; Parli CJ J Pharmacol Exp Ther; 1995 May; 273(2):695-701. PubMed ID: 7752072 [TBL] [Abstract][Full Text] [Related]
11. Absorption characteristics of azasetron from rectal and oral routes in rabbits. Moriyama Y; Arimori K; Nakano M Biol Pharm Bull; 1997 Jun; 20(6):701-3. PubMed ID: 9212995 [TBL] [Abstract][Full Text] [Related]
12. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Morrow GR; Roscoe JA; Kirshner JJ; Hynes HE; Rosenbluth RJ Support Care Cancer; 1998 May; 6(3):244-7. PubMed ID: 9629877 [TBL] [Abstract][Full Text] [Related]
13. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety. Adell A IDrugs; 2010 Dec; 13(12):900-10. PubMed ID: 21154150 [TBL] [Abstract][Full Text] [Related]
14. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog. Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791 [TBL] [Abstract][Full Text] [Related]
15. [From cocaine to innovative antiemetics. The medicinal chemistry of 5-ht3 receptor antagonists]. Zettl H; Schubert-Zsilavecz M; Siebert CD Pharm Unserer Zeit; 2007; 36(5):354-61. PubMed ID: 17722162 [No Abstract] [Full Text] [Related]
16. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? Gan TJ CNS Drugs; 2005; 19(3):225-38. PubMed ID: 15740177 [TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist]. Tsukagoshi S Gan To Kagaku Ryoho; 1999 Jun; 26(7):1001-8. PubMed ID: 10396331 [TBL] [Abstract][Full Text] [Related]
18. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting. Loewen PS; Marra CA; Zed PJ Can J Anaesth; 2000 Oct; 47(10):1008-18. PubMed ID: 11032279 [TBL] [Abstract][Full Text] [Related]
19. Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans. Franz PM; Mattiuz EL; Hatcher BL; DeSante KA; Breau AP; Occolowitz JL; Dorman DE; Schmid CR; Goldberg MJ; Rubin A Drug Metab Dispos; 1993; 21(2):249-54. PubMed ID: 8097693 [TBL] [Abstract][Full Text] [Related]
20. 5-HT3-receptor antagonists in the control of delayed-onset emesis. Gridelli C Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]